Catalent Inc (CTLT)
55.80
-0.16
(-0.29%)
USD |
NYSE |
Apr 18, 16:00
55.76
-0.04
(-0.08%)
After-Hours: 20:00
Catalent Enterprise Value: 14.86B for April 18, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 18, 2024 | 14.86B |
| April 17, 2024 | 14.89B |
| April 16, 2024 | 14.86B |
| April 15, 2024 | 14.91B |
| April 12, 2024 | 14.95B |
| April 11, 2024 | 15.06B |
| April 10, 2024 | 15.08B |
| April 09, 2024 | 15.08B |
| April 08, 2024 | 15.02B |
| April 05, 2024 | 15.03B |
| April 04, 2024 | 15.07B |
| April 03, 2024 | 15.02B |
| April 02, 2024 | 14.98B |
| April 01, 2024 | 14.97B |
| March 28, 2024 | 14.98B |
| March 27, 2024 | 14.98B |
| March 26, 2024 | 14.94B |
| March 25, 2024 | 14.97B |
| March 22, 2024 | 14.86B |
| March 21, 2024 | 14.87B |
| March 20, 2024 | 14.88B |
| March 19, 2024 | 14.89B |
| March 18, 2024 | 14.89B |
| March 15, 2024 | 14.94B |
| March 14, 2024 | 15.02B |
| Date | Value |
|---|---|
| March 13, 2024 | 15.01B |
| March 12, 2024 | 14.99B |
| March 11, 2024 | 15.04B |
| March 08, 2024 | 14.99B |
| March 07, 2024 | 14.96B |
| March 06, 2024 | 15.01B |
| March 05, 2024 | 15.07B |
| March 04, 2024 | 15.07B |
| March 01, 2024 | 15.11B |
| February 29, 2024 | 15.14B |
| February 28, 2024 | 15.25B |
| February 27, 2024 | 15.29B |
| February 26, 2024 | 15.31B |
| February 23, 2024 | 15.40B |
| February 22, 2024 | 15.33B |
| February 21, 2024 | 15.30B |
| February 20, 2024 | 15.26B |
| February 16, 2024 | 15.28B |
| February 15, 2024 | 15.16B |
| February 14, 2024 | 15.07B |
| February 13, 2024 | 14.94B |
| February 12, 2024 | 15.08B |
| February 09, 2024 | 15.03B |
| February 08, 2024 | 15.00B |
| February 07, 2024 | 14.99B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
8.271B
Minimum
May 13 2019
26.95B
Maximum
Sep 08 2021
16.48B
Average
15.42B
Median
Enterprise Value Benchmarks
| Eli Lilly and Co | 731.61B |
| Merck & Co Inc | 345.18B |
| Elanco Animal Health Inc | 12.11B |
| Moderna Inc | 30.45B |
| Avrobio Inc | -41.92M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -206.00M |
| Revenue (Quarterly) | 1.024B |
| Total Expenses (Quarterly) | 1.138B |
| EPS Diluted (Quarterly) | -1.13 |
| Gross Profit Margin (Quarterly) | 16.70% |
| Profit Margin (Quarterly) | -20.12% |
| Earnings Yield | -12.65% |
| Normalized Earnings Yield | -4.403 |